3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Plasma cell
1
Other solid neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Hodgkin Disease
1
Bacteremia
1
Interventions
Rituximab
530
Cyclophosphamide
425
Vincristine
219
Doxorubicin
192
fludarabine phosphate
177
Etoposide
167
Prednisone
166
fludarabine
162
Methotrexate
162
Cytarabine
157
Filgrastim
125
Dexamethasone
123
Lenalidomide
121
Granulocyte Colony-Stimulating Factor
116
Whole-Body Irradiation
107
Mycophenolic Acid
99
ibrutinib
97
Bendamustine Hydrochloride
91
Tacrolimus
88
Melphalan
85
Calcium Dobesilate
82
Peripheral Blood Stem Cell Transplantation
80
Bortezomib
80
Busulfan
78
obinutuzumab
64
ofatumumab
59
Radiotherapy
57
Cyclosporine
57
Antilymphocyte Serum
55
Brentuximab Vedotin
54
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Moxifloxacin
×
Lymphoid
×
Clear all
NCT00398411
2015-06-29
MoxiProph
University of Cologne
Phase 3
Completed
66 enrolled
15 charts